Decibel & Catalent partner for Hearing Loss Gene Therapy

Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss

Catalent and Decibel Therapeutics today announced they have signed an agreement for Catalent to provide Decibel with process and analytical development, and CGMP clinical manufacturing services, for Decibel’s lead investigational gene therapy product candidate, DB-OTO.